Andreas Burchert, MD, University of Marburg, Marburg, Germany, discusses the use of sorafenib as the new standard of care (SOC) for maintenance therapy after allogeneic transplantation for patients with FLT3+ acute myeloid leukemia (AML). Dr Burchert describes results from two randomized trials, both of which demonstrated the benefits of sorafenib after allogenic transplantation both in terms of relapse-free survival and overall survival. Dr Burchert also comments on the use of other tyrosine kinase inhibitors (TKIs) as maintenance therapy for FLT3+ AML. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.